OUR PRODUCTS
FORMULATION

Each tablet contains 10mg Cetirizine Dihydrochloride

DOSAGE AND ADMINISTRATION

Adult and children > 12 years: One tablet (10mg) daily. Children 6-12 years: ½ tablet (5mg) twice daily or 1 tablet (10mg) daily. Or as prescribed by the physician. In patients with renal insufficiency dosage should be reduced to ½ tablet daily. At present there are no data to suggest that the dose need to be reduced in elderly patients.

OVERDOSAGE

Drowsiness can be a symptom of overdosage occurring from administration of 50mg Cetirizine as a single dose. Overdosage in children may produce agitation. In case of massive overdosage, gastric lavage should be performed together with the usual supportive measures. To date, there is no specific antidote.

INDICATION

Treatment of perennial rhinitis, seasonal allergic rhinitis, chronic idiopathic urticaria, allergic conjunctivitis, and other forms of allergy. In addition to its increased potency as H1 antagonist, Cetirizine is also classified as a non-sedating antihistamine. Cetirizine dihydrochloride has a role in both skin and nasal allergic reactions with particular emphasis for its potential for inhibiting the Late Phase Response (LPR). CETIRIZINE apparently reduces allergic inflammation and cellular influx by mechanisms other than H1 blockade. CETIRIZINE also inhibits the delayed reactions observed after injection of platelet activating factor 9AFP, kalikrein and serum and PAF-induced eosinophil chemostaxis. In addition to its inhibiting effect on allergic skin reaction, CETIRIZINE also has an effect on the nasal allergic response. A significant reduction in sneezing and the amount of recovered albumn tame esterase activity and leukotriene C4 was observed.

CONTRAINDICATION

Do not prescribe to patients with a history of hypersensitivity to any of the components of Cetirizine and lactating women since Cetirizine is excreted in breast milk.

PRECAUTIONS

Studies in health volunteer at 20 to 25mg/day have not revealed effects on alertness or reaction time.However, patients are advised not to exceed the recommended dose of driving or operating machinery.

GERMANY
KOHLENSERSLAUTERN
67663 KAISERSLAUTERN
GERMANY

ASIA PACIFIC - PHILIPPINES
2204-C West Tektite Tower, Philippine Stock Exchange Center Exchange Rd.,
Ortigas Center, Pasig City,
Philippines

EMAIL
eisaac@verheilenpharma.com
info@verheilen.com
info@verheilenpharma.com

Verheilen Pharmaceuticals Inc. © 2015 All rights reserved.

Translate »